What ICD-10-CM code should be used for a malignant neoplasm of an unspecified site of the left female breast?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10-CM Code for Malignant Neoplasm of Unspecified Site of Left Female Breast

The appropriate ICD-10-CM code is C50.912 - Malignant neoplasm of unspecified site of left female breast.

Understanding the Code Structure

ICD-10-CM provides enhanced specificity compared to its predecessor ICD-9-CM, particularly through the incorporation of laterality (right, left, bilateral) directly into diagnostic codes 1. This granular approach allows for more precise documentation and improved disease pattern analysis.

Code Breakdown for Breast Malignancies

The C50 series covers malignant neoplasms of the breast, with the following structure:

  • C50.9 = Malignant neoplasm of breast of unspecified site
  • C50.91 = Malignant neoplasm of breast of unspecified site, female
  • C50.912 = Malignant neoplasm of breast of unspecified site, left female breast

For comparison:

  • C50.911 would be used for the right female breast
  • C50.919 would be used when laterality is unspecified

Clinical Documentation Requirements

Proper specimen handling and pathology reporting must include laterality specifications 2, 3. The guidelines consistently emphasize that excised tissue should be submitted for pathology examination with:

  • Appropriate clinical history
  • Anatomic site specifications, including laterality (right or left breast)
  • Quadrant location when known
  • Proper specimen orientation for the pathologist

Important Coding Considerations

When This Code Applies

Use C50.912 when:

  • The malignancy is confirmed as breast cancer
  • The patient is female
  • The affected breast is the left side
  • The specific quadrant or precise anatomical subsite within the breast is not documented or unknown

When More Specific Codes Should Be Used

If the specific breast quadrant or anatomical location is known, use more specific codes:

  • C50.011 (nipple and areola, left female breast)
  • C50.111 (central portion, left female breast)
  • C50.211 (upper-inner quadrant, left female breast)
  • C50.311 (lower-inner quadrant, left female breast)
  • C50.411 (upper-outer quadrant, left female breast)
  • C50.511 (lower-outer quadrant, left female breast)
  • C50.811 (overlapping sites, left female breast)

Clinical Context and Pitfalls

Common pitfall: Despite the increased specificity available in ICD-10-CM, studies show that 33.3% of codes used are unspecified variants, representing a 108.5% increase in unspecified code usage compared to ICD-9-CM 4. This suggests underutilization of available detail.

Best practice: Always document the specific anatomical location when known during clinical examination or pathological evaluation to enable use of the most specific code possible, as this improves data quality for treatment planning, research, and outcomes analysis.

The laterality specification is particularly critical for breast cancer management, as it affects surgical planning, radiation therapy targeting, and surveillance strategies for potential contralateral disease.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.